PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 21881571-6 2011 The mGluR(2/3) agonist LY379268 dose -dependently reduced reinstatement in all groups, but was more effective at low doses in the SW and RW groups. LY 379268 23-31 glutamate receptor, metabotropic 2 Mus musculus 4-13 34010316-5 2021 Compared with that in the sham control group, chronic LY379268 application (mGluR2/3 agonist; 0.40 mug/day) to the dorsal medulla oblongata for 6 weeks reduced the progression of hypertension in 6-week-old SHRs as indicated by the 40 mmHg reduction in systolic blood pressure and promoted their parasympathetic nervous activity as evidenced by the heart rate variability. LY 379268 54-62 glutamate receptor, metabotropic 2 Mus musculus 76-84 17537525-1 2007 We previously reported that systemic or central amygdala injections of the mGluR(2/3) agonist LY379268 (which decreases glutamate release) prevented enhanced cue-induced cocaine seeking in extinction tests after prolonged withdrawal (incubation of cocaine craving). LY 379268 94-102 glutamate receptor, metabotropic 2 Mus musculus 75-84 16834996-1 2006 We recently reported that systemic injections of the mGluR(2/3) agonist LY379268, which decreases evoked glutamate release, attenuate context- and discrete cue-induced reinstatement of heroin seeking, but not heroin self-administration. LY 379268 72-80 glutamate receptor, metabotropic 2 Mus musculus 53-62 20969570-6 2010 In addition significant reductions in extracellular glutamate were seen with locally applied omega-conotoxin (MVIIC; ~ 50%; calcium channel blocker), and the mGluR(2/3) agonist, LY379268 (~ 20%), and a significant increase with the mGluR(2/3) antagonist LY341495 (~ 40%), effects all consistent with a large neuronal contribution to the resting glutamate levels. LY 379268 178-186 glutamate receptor, metabotropic 2 Mus musculus 158-167 20969570-6 2010 In addition significant reductions in extracellular glutamate were seen with locally applied omega-conotoxin (MVIIC; ~ 50%; calcium channel blocker), and the mGluR(2/3) agonist, LY379268 (~ 20%), and a significant increase with the mGluR(2/3) antagonist LY341495 (~ 40%), effects all consistent with a large neuronal contribution to the resting glutamate levels. LY 379268 178-186 glutamate receptor, metabotropic 2 Mus musculus 232-241 16893525-0 2007 Systemic and central amygdala injections of the mGluR(2/3) agonist LY379268 attenuate the expression of incubation of cocaine craving. LY 379268 67-75 glutamate receptor, metabotropic 2 Mus musculus 48-57 34416343-0 2021 Rescue of BDNF Expression by the Thalamic Parafascicular Nucleus with Chronic Treatment with the mGluR2/3 Agonist LY379268 may Contribute to the LY379268 Rescue of Enkephalinergic Striatal Projection Neurons in R6/2 Huntington"s Disease Mice. LY 379268 114-122 glutamate receptor, metabotropic 2 Mus musculus 97-105 34416343-0 2021 Rescue of BDNF Expression by the Thalamic Parafascicular Nucleus with Chronic Treatment with the mGluR2/3 Agonist LY379268 may Contribute to the LY379268 Rescue of Enkephalinergic Striatal Projection Neurons in R6/2 Huntington"s Disease Mice. LY 379268 145-153 glutamate receptor, metabotropic 2 Mus musculus 97-105 34416343-1 2021 We have found that daily subcutaneous injection with a maximum tolerated dose of the mGluR2/3 agonist LY379268 (20 mg/kg) beginning at 4 weeks of age dramatically improves the motor, neuronal and neurochemical phenotype in R6/2 mice, a rapidly progressing transgenic model of Huntington"s disease (HD). LY 379268 102-110 glutamate receptor, metabotropic 2 Mus musculus 85-93 34330748-5 2021 Treatment of both male and female zQ175 mice with the potent and selective mGluR2/3 agonist LY379268 for either 4 or 8 weeks improves both limb coordination and locomotor function in all mice. LY 379268 92-100 glutamate receptor, metabotropic 2 Mus musculus 75-83 34330748-11 2021 Significance Statement The mGluR2/3 agonist LY379268 improves motor impairments and reduces pathology in male and female zQ175 Huntington"s mice. LY 379268 44-52 glutamate receptor, metabotropic 2 Mus musculus 27-35 35091538-4 2022 We found that an obesogenic diet reduced goal-directed control and that systemic injection of LY379268, a Group II metabotropic glutamate receptor (mGluR2/3) agonist, returned goal-directed responding in these rats. LY 379268 94-102 glutamate receptor, metabotropic 2 Mus musculus 148-156 32534177-7 2021 The current study evaluated the effect of mGluR2/3 agonist LY379268 (LY37) in BLA on stress and fear memory induced changes in sleep, EEG spectra, behavioral fear expression and physiological stress. LY 379268 59-67 glutamate receptor, metabotropic 2 Mus musculus 42-50 32534177-7 2021 The current study evaluated the effect of mGluR2/3 agonist LY379268 (LY37) in BLA on stress and fear memory induced changes in sleep, EEG spectra, behavioral fear expression and physiological stress. LY 379268 59-63 glutamate receptor, metabotropic 2 Mus musculus 42-50 22820300-0 2012 BDNF may play a differential role in the protective effect of the mGluR2/3 agonist LY379268 on striatal projection neurons in R6/2 Huntington"s disease mice. LY 379268 83-91 glutamate receptor, metabotropic 2 Mus musculus 66-74 22659409-3 2013 Following self-administration and subsequent extinction training, rats were pretreated with the selective mGluR(2/3) agonist LY379268 (variable dose, 0-3 mg/kg), exposed to METH-paired cues or a priming injection of METH (1 mg/kg), and tested for reinstatement of METH-seeking behavior. LY 379268 125-133 glutamate receptor, metabotropic 2 Mus musculus 106-115 31580222-0 2019 The mGluR2/3 agonist LY379268 reverses NMDA receptor antagonist effects on cortical gamma oscillations and phase coherence, but not working memory impairments, in mice. LY 379268 21-29 glutamate receptor, metabotropic 2 Mus musculus 4-12 31580222-3 2019 AIMS: We studied relationships between cognitive impairment and gamma abnormalities following NMDAr antagonism, and attempted to reverse deficits with the metabotropic glutamate receptor type 2/3 (mGluR2/3) agonist LY379268. LY 379268 215-223 glutamate receptor, metabotropic 2 Mus musculus 197-205 24067300-9 2014 In contrast, reducing glutamatergic transmission in the NAc via bilateral injections of the metabotropic glutamate receptor-2/3 agonist LY379268 reduced drinking in dependent (EtOH) mice to nondependent (CTL) levels, whereas having a more modest effect in decreasing ethanol consumption in CTL mice. LY 379268 136-144 glutamate receptor, metabotropic 2 Mus musculus 92-125 22659409-5 2013 However, LgA rats demonstrated greater sensitivity to mGluR(2/3) stimulation with attenuated responding during cue-induced reinstatement after 0.3 mg/kg and higher doses of LY379268, whereas ShA rats decreased cue-induced reinstatement behavior following 1.0 mg/kg and 3.0 mg/kg LY379268. LY 379268 173-181 glutamate receptor, metabotropic 2 Mus musculus 54-63 22659409-5 2013 However, LgA rats demonstrated greater sensitivity to mGluR(2/3) stimulation with attenuated responding during cue-induced reinstatement after 0.3 mg/kg and higher doses of LY379268, whereas ShA rats decreased cue-induced reinstatement behavior following 1.0 mg/kg and 3.0 mg/kg LY379268. LY 379268 279-287 glutamate receptor, metabotropic 2 Mus musculus 54-63 22820300-1 2012 We have found that daily subcutaneous injection with a maximum tolerated dose (MTD) of the mGluR2/3 agonist LY379268 (20mg/kg) beginning at 4 weeks dramatically improves the phenotype in R6/2 mice. LY 379268 108-116 glutamate receptor, metabotropic 2 Mus musculus 91-99 22472187-2 2012 Since corticostriatal terminals possess mGluR2/3 autoreceptors, whose activation dampens glutamate release, we tested the ability of the mGluR2/3 agonist LY379268 to improve the phenotype in R6/2 HD mice with 120-125 CAG repeats. LY 379268 154-162 glutamate receptor, metabotropic 2 Mus musculus 137-145